Investigating a new treatment target for lung injury caused by influenza
Targeting RIPK3 in Flu-Associated Lung Injury
This study is looking at how a protein called RIPK3 affects lung damage and inflammation when people get the flu, with the hope of finding new ways to help treat severe lung problems during flu outbreaks.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10689229 on NIH RePORTER |
What this research studies
This research focuses on understanding how the RIPK3 protein contributes to lung injury and inflammation during influenza A virus infections. By targeting RIPK3, the study aims to develop new therapeutic strategies that could reduce the severe lung damage associated with both seasonal and pandemic influenza. The approach involves exploring the role of RIPK3 in a specific type of cell death called necroptosis, which is linked to serious respiratory conditions like Acute Respiratory Distress Syndrome (ARDS). The research could lead to innovative treatments that improve patient outcomes during influenza outbreaks.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who experience severe respiratory symptoms due to influenza, particularly those at high risk for complications like ARDS.
Not a fit: Patients who do not have influenza or related respiratory conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce lung injury and improve survival rates for patients with severe influenza infections.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for treating inflammatory conditions, indicating potential for success in this novel approach.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Balachandran, Siddharth — Research Inst of Fox Chase Can Ctr
- Study coordinator: Balachandran, Siddharth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.